Edwards Lifesciences v Meril (CFI, 17 October 2025)
| Date | 17 October 2025 |
|---|---|
| Court | CFI |
| Division | Munich (DE) Local Division |
| Type of action | Generic Order |
| Case number(s) | UPC_CFI_404/2025;UPC_CFI_405/2025 |
| Registry reference | UPC_CFI_404/2025and · UPC_CFI_405/2025 |
| Parties | Edwards Lifesciences Corporation v. Meril GmbH a.o. |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By decision of 17 October 2025 (UPC_CFI_404/2025 and UPC_CFI_405/2025, EP 3 669 828), the judge-rapporteur of the Munich Local Division ordered Meril GmbH, Meril Life Sciences and Meril Italy to pay Edwards Lifesciences EUR 771,649.56 in costs within 20 days, in the joined infringement action and counterclaim. Only a small share of the travel expenses remained in dispute. The decision takes a flexible approach to reviewing representation costs, expressly departing from an order of the Brussels Local Division.
Question
Are travel costs relating to several representatives, in-person meetings, taxis and breakfasts reasonable and proportionate costs recoverable under Art. 69(1) UPCA?
Decision
Yes. Cost proceedings are summary in nature and the judge-rapporteur has broad discretion over procedure, whether costs were incurred and whether they are reasonable and proportionate (section II.1, Rule 156.2 RoP). Neither the UPCA nor the Rules limit the number of representatives or firms acting for a party. Each one’s involvement and in-person meetings are reasonable where the representative considers them necessary, as evidence is hard to produce (section II.2.a). As the disputed amount is a small percentage of the ceiling and of representation costs, the court may award it without detailed review. Taxis and ride-hailing are justified, since representatives can work while travelling (section II.2.b). Edwards having withdrawn certain items (meals, laundry, one representative’s travel), the balance is awarded. The decision has no numbered paragraphs.
Key points for practice
- In a complex case, the number of representatives and firms is not in itself a reason to reduce recoverable costs.
- Where the disputed share is marginal compared with the ceiling, the division may decide without a line-by-line review.
Provisions applied
- Agreement on a Unified Patent Court
- Art. 69(1) and 82
- Statute of the Court
- Art. 37(2)
- Rules of Procedure
- Rules 151, 156, 157, 262.2 and 262.3
- Case law cited
- Court of Appeal, UPC_CoA_618/2024 (paragraph 10), Brussels Local Division, 25 July 2025 (UPC_CFI_131/2025), from which the order departs, Edwards Lifesciences v Meril, 4 April 2025 (Munich Local Division, decision ordering the defendants to bear the costs)
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Going further
Lexicon: Written procedure (UPC), Court fees and costs (UPC).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Parties
- claimantEdwards Lifesciences Corporation41 decisions in the corpusFollow this party
- defendantMeril GmbH a.oFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Generic Order
- Outcome (Dhenne Avocats summary)
- Les défenderesses Meril doivent payer à Edwards 771 649,56 euros de frais sous 20 jours, les frais de déplacement contestés étant jugés raisonnables et proportionnés.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 3 669 828mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- OrthoApnea v *** (CFI, 25 July 2025) cited in this record
- Edwards Lifesciences v Meril (CFI, 4 April 2025) cited in this record
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 3 669 828Prosthetic heart valve recorded proprietor: Edwards Lifesciences Corp | Mentioned in the analysis (role not qualified) Also mentioned in 11 other decision(s): Edwards Lifesciences v Meril (CFI, 4 April 2025) · Edwards Lifesciences v Meril (CFI, 12 August 2026) · Edwards Lifesciences v Meril (CFI, 26 June 2026) · Edwards Lifesciences v Meril (CFI, 3 June 2025) · Edwards Lifesciences v Meril (CFI, 14 April 2025) · Edwards Lifesciences v Meril (CFI, ORD_60824/2024, 9 April 2025) · Edwards Lifesciences v Meril (CFI, 5 February 2025) · Edwards Lifesciences v Meril (CFI, 20 December 2024) | not recorded | not recorded | not recorded | Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.